Product Description
Mechanisms of Action: ADRA Antagonist,ADRB Agonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Argentina | Brazil | Chile | Egypt | India | Indonesia | Ireland | Italy | New Zealand | Peru | Philippines | Portugal | Taiwan | Ukraine | Venezuela
Approved Indications: None
Known Adverse Events: None
Company: University of New Mexico
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Multiple Sclerosis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
NCT03752307 | P2 |
Completed |
Multiple Sclerosis |
2023-07-06 |